Drug maker OBI Pharma Inc (台灣浩鼎) yesterday said that it will start generating revenue this year, driven by the planned launch of its DIFCID antibiotic in Taiwan by the end of the second quarter.
The company has failed to post revenue since 2011, before its started trading its shares on the Emerging Stock Market in 2012.
“We are currently finalizing talks with the National Health Insurance Administration concerning drug prices, as well as with our suppliers regarding materials prices,” general manager Amy Huang (黃秀美) said.
However, Huang said that the market for DIFCID in Taiwan is small because antibiotics are not overused in the nation and it is not in need of new kinds of antibiotics.
The company could continue its loss-making streak this year, since it is expected to spend between NT$600 million and NT$700 million (US$19.77 million and US$49 million) on research and development. OBI Pharma said that most of the amount will be used to finance clinical trials for its drugs.
In the first half of last year, the company spent NT$177.82 million on research and development, according to its stock exchange filing.
Over the same period, OBI Pharma reported NT$202.47 million in losses, an increase from the NT$101.03 million in losses it posted a year ago that was the result of more spending on research and development, its filing showed.
The construction of Amaran Biotechnology Inc’s (潤雅生技) new factory in the Hsinchu Biomedical Science Park (新竹生醫園區) will be operational at the end of this year after the factory receives Good Manufacturing Practice its (GMP) certificate from the government, Huang said, adding that the factory will make botox for OBI Pharma.
According to Huang, the company will complete data collection for phase-three clinical trails for OBI-822, which is used to treat breast cancer, in Taiwan by the end of June.
The company plans to file for a permit to sell OBI-822 in Taiwan in 2016 and in the US in 2018, it said.
The firm is to launch the cancer drug in the US, Taiwan and China on its own, but is seeking partners to sell the medication in Europe and Japan, it said.
OBI Pharma also acquired a new monoclonal antibody to treat cancer last year from Academia Sinica, Huang said, adding that the drug is in the pre-clinical trial stage.
It also has plans to shift to the GRETAI Securities Market by the end of this year.
OBI Pharma stock fell 1.51 percent to NT$227.94 yesterday on the Emerging Stock Market.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six